BYSI - BeyondSpring Pharma Average Forecast Price

BeyondSpring Inc. (BYSI) faces risks related to the protection of foreign patents and logistical complexities in raw material supplies. This chart illustrates the asset's price action, where the current figure stands at 1.25. The company is revising its product portfolio following regulatory rejections, counting on investments from China. The business relies on establishing an ancillary treatment system, integrating Plinabulin into therapy to protect patients' blood cells.

BeyondSpring (BYSI): Analyst Consensus Forecast from 07/04/2022 to 11/11/2026

Analytical breakdowns for BeyondSpring Pharma (BYSI)

- current price and projected stock value:

Price Chart beyondspringpharma.com|BYSI - Consensus Target

- market capitalization statistics:

Market Value BeyondSpring Pharma|BYSI - Total Company Value

- shareholders' equity book value data:

Net Assets per Share BeyondSpring|BYSI - Book Capitalization|Market Capitalization to Book Value beyondspringpharma.com|BYSI - Company Total Assets

- issuer credit burden and liquidity indicators:

- net income and valuation ratios data:

BYSI - Net Profit|Projected Future Earnings BeyondSpring Inc.|BYSI - Price to Earnings Ratio|Future Price to Earnings BeyondSpring, Inc.|BYSI - Price/Earnings to Growth Multiple|Business Value to Operating Income Before Depreciation BeyondSpring Pharma|BYSI - Profit before payment of interest, taxes and amortization|Net earnings per one share for the last twelve months BeyondSpring|BYSI - Earnings per share for the last twelve months|Year-over-year earnings per share growth for the last 12 months beyondspringpharma.com|BYSI - Earnings growth in current year|Expected earnings per share growth for next year BeyondSpring Inc.

Fundamental company analysis:beyondspringpharma.com (BYSI)

This indicator reflects the aggregate expert expectation regarding the asset's fair value, where the stability of the line confirms the transparency of the business model and the absence of sharp revisions to fundamental valuations. By analyzing the consensus valuation trend, an investor can assess market confidence in the scalability of BeyondSpring Inc. (BYSI) and the potential of Plinabulin within the context of innovative oncology therapy development.

Competing companies